Description
Recent literature demonstrates that colorectal cancer (CRC) is now the most common type of cancer in the Kingdom of Saudi Arabia (KSA). For people undergoing treatment for CRC, pharmacists will play a pivotal role in their health care team.
The objective of this online program is to help educate and support pharmacists in the KSA in understanding the current landscape of CRC – genetic aberrations, risk factors, incidence, and selected newly approved therapies. There is also discussion about common adverse events associated with guideline-recommended treatment of CRC, and the role of pharmacists to help mitigate these adverse events in their patients.
This program has received an educational grant or in-kind support from Novartis.